Smac mimetics and TRAIL cooperate to induce MLKL-dependent necroptosis in Burkitt's lymphoma cell lines.

Autor:	Koch A; Institute for Experimental Cancer Research in Pediatrics, Goethe-University Frankfurt, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany., Jeiler B; Institute for Experimental Cancer Research in Pediatrics, Goethe-University Frankfurt, Germany., Roedig J; Institute for Experimental Cancer Research in Pediatrics, Goethe-University Frankfurt, Germany., van Wijk SJL; Institute for Experimental Cancer Research in Pediatrics, Goethe-University Frankfurt, Germany., Dolgikh N; Institute for Experimental Cancer Research in Pediatrics, Goethe-University Frankfurt, Germany., Fulda S; Institute for Experimental Cancer Research in Pediatrics, Goethe-University Frankfurt, Germany. Electronic address: simone.fulda@kgu.de.
Jazyk:	angličtina
Zdroj:	Neoplasia (New York, N.Y.) [Neoplasia] 2021 May; Vol. 23 (5), pp. 539-550. Date of Electronic Publication: 2021 May 07.
DOI:	10.1016/j.neo.2021.03.003
Abstrakt:	Burkitt's lymphoma (BL) is a highly aggressive form of B-cell non-Hodgkin's lymphoma. The clinical outcome in children with BL has improved over the last years but the prognosis for adults is still poor, highlighting the need for novel treatment strategies. Here, we report that the combinational treatment with the Smac mimetic BV6 and TRAIL triggers necroptosis in BL when caspases are blocked by zVAD.fmk (TBZ treatment). The sensitivity of BL cells to TBZ correlates with MLKL expression. We demonstrate that necroptotic signaling critically depends on MLKL, since siRNA-induced knockdown and CRISPR/Cas9-mediated knockout of MLKL profoundly protect BL cells from TBZ-induced necroptosis. Conversely, MLKL overexpression in cell lines expressing low levels of MLKL leads to necroptosis induction, which can be rescued by pharmacological inhibitors, highlighting the important role of MLKL for necroptosis execution. Importantly, the methylation status analysis of the MLKL promoter reveals a correlation between methylation and MLKL expression. Thus, MLKL is epigenetically regulated in BL and might serve as a prognostic marker for treatment success of necroptosis-based therapies. These findings have crucial implications for the development of new treatment options for BL. (Copyright © 2021. Published by Elsevier Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu